These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 12000860)

  • 1. The immunotherapy of patients with ovarian cancer.
    Hwu P; Freedman RS
    J Immunother; 2002; 25(3):189-201. PubMed ID: 12000860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
    Wang W; Zou W; Liu JR
    Gynecol Oncol; 2018 Oct; 151(1):1-3. PubMed ID: 30243508
    [No Abstract]   [Full Text] [Related]  

  • 3. Ovarian Cancer Immunotherapy: Turning up the Heat.
    Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.
    Santin AD; Bellone S; Palmieri M; Bossini B; Cane' S; Bignotti E; Roman JJ; Cannon MJ; Pecorelli S
    Int J Gynecol Cancer; 2004; 14(1):64-75. PubMed ID: 14764031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy opportunities in ovarian cancer.
    Chu CS; Kim SH; June CH; Coukos G
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):243-57. PubMed ID: 18279065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.
    Freedman RS; Platsoucas CD
    Cancer Treat Res; 1996; 82():115-46. PubMed ID: 8849947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
    Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
    Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy against ovarian cancer.
    Mittica G; Capellero S; Genta S; Cagnazzo C; Aglietta M; Sangiolo D; Valabrega G
    J Ovarian Res; 2016 May; 9(1):30. PubMed ID: 27188274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy in epithelial ovarian carcinoma: hope and reality].
    Lavoué V; Foucher F; Henno S; Bauville E; Catros V; Cabillic F; Levêque J
    J Gynecol Obstet Biol Reprod (Paris); 2014 Mar; 43(3):198-210. PubMed ID: 24230482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in ovarian cancer.
    Odunsi K
    Ann Oncol; 2017 Nov; 28(suppl_8):viii1-viii7. PubMed ID: 29232467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.
    Wefers C; Lambert LJ; Torensma R; Hato SV
    Gynecol Oncol; 2015 May; 137(2):335-42. PubMed ID: 25727651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study.
    Wright SE; Rewers-Felkins KA; Quinlin IS; Phillips CA; Townsend M; Philip R; Dobrzanski MJ; Lockwood-Cooke PR; Robinson W
    J Immunother; 2012; 35(2):196-204. PubMed ID: 22306908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for ovarian cancer: recent advances and perspectives.
    Zsiros E; Tanyi J; Balint K; Kandalaft LE
    Curr Opin Oncol; 2014 Sep; 26(5):492-500. PubMed ID: 25036883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel immunologic strategies in ovarian carcinoma.
    Freedman RS; Ioannides CG; Mathioudakis G; Platsoucas CD
    Am J Obstet Gynecol; 1992 Nov; 167(5):1470-8. PubMed ID: 1332480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).
    Oei AL; Sweep FC; Thomas CM; Boerman OC; Massuger LF
    Int J Oncol; 2008 Jun; 32(6):1145-57. PubMed ID: 18497976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging immunotherapies in ovarian cancer.
    Ojalvo LS; Nichols PE; Jelovac D; Emens LA
    Discov Med; 2015 Sep; 20(109):97-109. PubMed ID: 26463091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
    Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.
    Santin AD; Bellone S; Ravaggi A; Pecorelli S; Cannon MJ; Parham GP
    Obstet Gynecol; 2000 Sep; 96(3):422-30. PubMed ID: 10960637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities in immunotherapy of ovarian cancer.
    Coukos G; Tanyi J; Kandalaft LE
    Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i11-i15. PubMed ID: 27141063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in ovarian cancer.
    Krishnan V; Berek JS; Dorigo O
    Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.